Humana Inc. (NYSE:HUM) Stock Holdings Trimmed by Kintegral Advisory LLC

Kintegral Advisory LLC decreased its holdings in Humana Inc. (NYSE:HUMFree Report) by 4.5% in the 4th quarter, HoldingsChannel reports. The firm owned 3,732 shares of the insurance provider’s stock after selling 174 shares during the quarter. Kintegral Advisory LLC’s holdings in Humana were worth $950,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Deseret Mutual Benefit Administrators grew its position in Humana by 18.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 399 shares of the insurance provider’s stock valued at $101,000 after buying an additional 61 shares in the last quarter. Camelot Portfolios LLC acquired a new stake in shares of Humana in the 4th quarter worth approximately $574,000. Peregrine Asset Advisers Inc. bought a new position in shares of Humana in the fourth quarter valued at approximately $4,327,000. Transcend Capital Advisors LLC boosted its holdings in shares of Humana by 399.7% in the fourth quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock valued at $924,000 after acquiring an additional 2,914 shares in the last quarter. Finally, Paradigm Asset Management Co. LLC increased its stake in shares of Humana by 766.7% during the fourth quarter. Paradigm Asset Management Co. LLC now owns 2,600 shares of the insurance provider’s stock valued at $660,000 after acquiring an additional 2,300 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.32% of the stock is currently owned by insiders.

Humana Price Performance

Shares of NYSE:HUM opened at $255.77 on Friday. The company has a market cap of $30.80 billion, a P/E ratio of 25.71, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56. The company’s fifty day moving average is $269.41 and its two-hundred day moving average is $290.00. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUMGet Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.38%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Analysts Set New Price Targets

A number of research firms have weighed in on HUM. Piper Sandler upped their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Morgan Stanley cut their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Finally, Wells Fargo & Company reduced their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Humana presently has an average rating of “Hold” and an average target price of $285.68.

Read Our Latest Analysis on Humana

About Humana

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.